“This study is a breakthrough because it is the first trial to show that a non-hormonal drug can induce durable complete remissions in recurrent prostate cancer patients with BRCA2 mutations—one of the most aggressive subtypes of this disease,” says Emmanuel S. Antonarakis, MD.
Data from the study showed that 45% of biopsies with benign results or low-grade cancers could be reduced overall by using Stockholm3 compared with PSA.
"The scale of that linkage and the manner with which we were able to do it is really exciting and opens the door for a lot of future discovery," says Michael S. Leapman, MD, MHS.
"This study demonstrates that for up to 10 years after diagnosis, approximately 50% of men with low-risk prostate cancer can safely remain on AS, without cancer progression or treatment, since less than 1% died of prostate cancer," writes Badar M. Mian, MD.
Data showed that Hispanic patients were consistently underrepresented in clinical trials, while Black participants tended to be overrepresented.
“This highlights a need for physicians to better integrate patient preferences into their treatment recommendations," says Jonathan Bergman, MD, MPH.
Data from phase 2 of the SANS-UUI trial are expected to support an application to the FDA for approval of the device in patients with urge urinary incontinence.
The study has enrolled 8 patients to assess the safety and efficacy of the device in sealed vasectomy procedures.
Topline results from the phase 3 ARANOTE trial showed a statistically and clinically significant improvement in rPFS with the addition of darolutamide to ADT vs ADT alone.
The guideline includes 38 recommendations on managing incontinence following treatment for localized prostate cancer or benign prostatic hyperplasia.
